MedTrace Logo

Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

NCT05442463 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-03-27

No results posted yet for this study

Summary

1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women.
2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.

Conditions

  • Hormone Therapy

Interventions

DRUG

Captopril Tablets

Captorpril challenge to each participant

DRUG

Iohexol

Iohexol infusion to evaluate measured GFR

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Sofia Ahmed, MD · Alberta Health services

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05442463 on ClinicalTrials.gov